Clinical trials: Genital Neoplasms, Male
Prostate Cancer
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Oligo-metastatic prostate cancer (OMPCa) is considered as an intermediated state between localized and poly-metastatic disease. Various retrospective studies and prospective clinical trials are carrying out to validate whether…
- Trial name
- NCT05212857
- Testing
- Leuprolide acetate, Goserelin acetate, Triptorelin acetate
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation.
- Conditions
- Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, Metastatic Castration-resistant Prostate Cancer
- Trial name
- NCT07288359
- Testing
- GVV858, Fulvestrant, Letrozole
- Where
- 16 sites in United States, Canada and 9 more
- Volunteers
- 205 people
- Sponsor
- Novartis Pharmaceuticals
Hormone-Resistant Prostate Cancer, Recurrent Prostate Carcinoma
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
This randomized phase II trial is studying how well giving pazopanib with or without bicalutamide works in treating patients with prostate cancer that did not respond to hormone therapy.
- Trial name
- NCT00486642
- Testing
- Bicalutamide, Laboratory Biomarker Analysis, Pazopanib Hydrochloride
- Where
- 6 sites in Canada
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
This phase III trial studies how well hypofractionated radiation therapy works compared to the conventional one in treating patients with prostate cancer.
- Conditions
- Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03987386
- Testing
- Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 186 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Neoplasm Metastasis
A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer
The purpose of this study is to evaluate the effectiveness of the investigational radioisotope Radium-223 in treatment of men with prostate cancer and bone metastases that no longer respond to hormonal treatment.
- Trial name
- NCT00459654
- Testing
- Radium-223 dichloride (BAY88-8223), Saline
- Where
- 3 sites in Sweden, United Kingdom
- Volunteers
- 64 people
- Sponsor
- Bayer
NRG1 Fusion, Pancreatic Cancer
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus is providing single patient/named access to the HER2/HER3 bispecific antibody, MCLA-128, to patients with advanced NRG1-fusion positive solid tumor under this early access program who are ineligible for an ongoing MCLA-128…
- Conditions
- NRG1 Fusion, Pancreatic Cancer, Non Small Cell Lung Cancer, Solid Tumor, Unspecified, Adult
- Trial name
- NCT04100694
- Testing
- MCLA-128
- Sponsor
- Merus B.V.
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Prostate Cancer
RADAR Trial - Randomised Androgen Deprivation and Radiotherapy
The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2)…
- Trial name
- NCT00193856
- Testing
- Leuprorelin Acetate, Zoledronic Acid, Conventional external beam therapy
- Where
- 24 sites in Australia, New Zealand
- Volunteers
- 1,071 people
- Sponsor
- Trans Tasman Radiation Oncology Group
Infection
PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy
Approximately one million transrectal prostate biopsies are performed annually in the U.S., and the risk of post- biopsy infection is increasing due to greater antibiotic resistance of rectal flora.
- Trial name
- PREVENT (NCT04843566)
- Testing
- Transperineal MRI-guided prostate biopsy, Transrectal MRI-guided prostate biopsy, Antibiotic (prophylaxis)
- Where
- 10 sites in United States
- Volunteers
- 687 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
PROvenge Treatment and Early Cancer Treatment
The PROTECT-PROvenge Treatment and Early Cancer Treatment trial was a Phase III trial for patients with hormone sensitive prostate cancer. The study was conducted at over 15 participating centers throughout the US.
- Trial name
- PROTECT (NCT00779402)
- Testing
- Control, Sipuleucel-T
- Where
- 18 sites in United States
- Volunteers
- 176 people
- Sponsor
- Dendreon
Prostate Cancer
A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer
The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).
- Trial name
- NCT00683475
- Testing
- IMC-A12, Mitoxantrone, Prednisone
- Where
- 36 sites in United States
- Volunteers
- 138 people
- Sponsor
- Eli Lilly and Company
Stage IV Prostate Cancer
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
This pilot phase II trial studies the side effects and how well pembrolizumab and cryosurgery work with short term androgen ablation to treat patients with prostate cancer that has traveled from the original tumor, through the…
- Trial name
- NCT02489357
- Testing
- Cryosurgery, Degarelix, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel
The purpose of this study is to first determine the highest dose of LDE225 combined wtih Docetaxel and Prednisone that can be given that does not cause unacceptable side effects when given to patients with castrate resistant…
- Trial name
- NCT02182622
- Testing
- Docetaxel, Prednisone, LDE225
- Where
- United States
- Sponsor
- Martin Gutierrez
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Symptom Management in African-American Men With Localized Prostate Cancer
RATIONALE: Gathering information about symptom management from patients with localized prostate cancer may help doctors improve patients' quality of life.
- Trial name
- NCT00767845
- Testing
- questionnaire/survey administration
- Where
- United States
- Sponsor
- Baylor College of Medicine
Prostate Cancer
Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients
Tremodi is an observational, non-interventional, prospective, open-label, non-comparative study that will collect real life data of a treatment with Depo-Eligard® in 3 different administrations in male prostate cancer patients.
- Trial name
- TREMODI (NCT01793077)
- Testing
- Depo-Eligard®
- Where
- 23 sites in Belgium
- Volunteers
- 259 people
- Sponsor
- Astellas Pharma Europe B.V.
Prostate Cancer
HIFU for Focal Ablation of Prostate Tissue: An Observational Study
The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through…
- Trial name
- NCT03620786
- Testing
- Sonablate HIFU device
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, Los Angeles
Prostate Cancer
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
Brachytherapy, or Transperineal implantation of the prostate (TPIP), is a recognized form of treatment for localized cancer of the prostate. TPIP has been used at the British Columbia Cancer Agency (BCCA) since 1998.
- Trial name
- NCT00175383
- Testing
- luteinizing hormone-releasing hormone (LHRH) short acting or long acting
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- University of British Columbia
Prostate Cancer
Randomized Controlled Trial of MRI Target Biopsy: Transrectal vs. Transperineal
This prospective study of comparing between Transrectal and transperineal prostate MRI targeted biopsy to provide evidence for clinicians to select the appropriate biopsy approach under different conditions.
- Trial name
- NCT03650153
- Testing
- Trans-rectal MRI targeted Biopsy, Trans-perineal MRI targeted Biopsy
- Where
- Saudi Arabia
- Volunteers
- 165 people
- Sponsor
- Princess Al-Johara Al-Ibrahim Cancer Research Center
Recurrent Prostate Cancer, Stage I Prostate Cancer
The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer
This randomized pilot phase I trial studies how well sargramostim after cryotherapy works in treating patients with prostate cancer.
- Conditions
- Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT02250014
- Testing
- cryotherapy, sargramostim
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.